S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
Copper Exploration Heating Up (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Copper Exploration Heating Up (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
Copper Exploration Heating Up (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Copper Exploration Heating Up (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
Copper Exploration Heating Up (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Copper Exploration Heating Up (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Copper Exploration Heating Up (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
Are the Short Sellers Still Right About Mullen Automotive stock? 
Copper Exploration Heating Up (Ad)
La-Z-Boy Reclines To More Comfortable Levels 
Is The Recovery Rally Here For SoFi?
Copper Exploration Heating Up (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:DAWN

Day One Biopharmaceuticals - DAWN Stock Forecast, Price & News

$21.22
-0.01 (-0.05%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$21.02
$22.70
50-Day Range
$18.04
$22.00
52-Week Range
$5.44
$28.35
Volume
436,870 shs
Average Volume
421,692 shs
Market Capitalization
$1.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.33

Day One Biopharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
71.2% Upside
$36.33 Price Target
Short Interest
Healthy
11.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.91mentions of Day One Biopharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$25.91 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.15) to ($2.19) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

612th out of 1,047 stocks

Pharmaceutical Preparations Industry

298th out of 512 stocks

DAWN stock logo

About Day One Biopharmaceuticals (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Receive DAWN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DAWN Stock News Headlines

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Down 5.9%
Day One Biopharmaceuticals, Inc. (DAWN)
Massive Insider Trade At Day One Biopharmaceutical
First Week of DAWN April 2023 Options Trading
Biotech ETF Tops in June: 5 Stocks That Outperform
See More Headlines
Receive DAWN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DAWN Company Calendar

Last Earnings
3/07/2022
Today
12/02/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/06/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DAWN
Fax
N/A
Employees
55
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$36.33
High Stock Price Forecast
$40.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+71.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-70,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.94 per share

Miscellaneous

Free Float
67,151,000
Market Cap
$1.56 billion
Optionable
Not Optionable
Beta
-2.29

Key Executives

  • Dr. Jeremy Bender M.B.A. (Age 50)
    Ph.D., CEO, Pres & Director
    Comp: $836.82k
  • Dr. Samuel C. Blackman M.D.Dr. Samuel C. Blackman M.D. (Age 53)
    Ph.D., Co-Founder & Chief Medical Officer
    Comp: $627.57k
  • Ms. Julie Papanek Grant M.B.A. (Age 40)
    Co-Founder & Director
    Comp: $41.81k
  • Mr. Charles N. York II (Age 45)
    COO, CFO & Sec.
    Comp: $714.34k
  • Dr. Mike Preigh Ph.D.
    Chief of Technology Operations
  • Mr. Adam Dubow (Age 55)
    Gen. Counsel
  • Ms. Jaa Roberson
    Chief People Officer
  • Dr. Davy Chiodin Ph.D.
    Pharm.D., Chief Devel. Officer













DAWN Stock - Frequently Asked Questions

Should I buy or sell Day One Biopharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Day One Biopharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DAWN shares.
View DAWN analyst ratings
or view top-rated stocks.

What is Day One Biopharmaceuticals' stock price forecast for 2023?

3 brokers have issued 1-year price objectives for Day One Biopharmaceuticals' stock. Their DAWN share price forecasts range from $34.00 to $40.00. On average, they expect the company's share price to reach $36.33 in the next twelve months. This suggests a possible upside of 71.2% from the stock's current price.
View analysts price targets for DAWN
or view top-rated stocks among Wall Street analysts.

How have DAWN shares performed in 2022?

Day One Biopharmaceuticals' stock was trading at $16.85 at the beginning of 2022. Since then, DAWN shares have increased by 25.9% and is now trading at $21.22.
View the best growth stocks for 2022 here
.

Are investors shorting Day One Biopharmaceuticals?

Day One Biopharmaceuticals saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 4,560,000 shares, a drop of 9.5% from the October 31st total of 5,040,000 shares. Based on an average daily volume of 607,300 shares, the days-to-cover ratio is presently 7.5 days. Currently, 11.6% of the company's shares are short sold.
View Day One Biopharmaceuticals' Short Interest
.

When is Day One Biopharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 6th 2023.
View our DAWN earnings forecast
.

How were Day One Biopharmaceuticals' earnings last quarter?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) posted its quarterly earnings results on Monday, March, 7th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.01.

When did Day One Biopharmaceuticals IPO?

(DAWN) raised $126 million in an initial public offering on Thursday, May 27th 2021. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Day One Biopharmaceuticals' stock symbol?

Day One Biopharmaceuticals trades on the NASDAQ under the ticker symbol "DAWN."

Who are Day One Biopharmaceuticals' major shareholders?

Day One Biopharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Atlas Venture Life Science Advisors LLC (11.12%), Canaan Partners XI LLC (9.48%), Vanguard Group Inc. (3.56%), BlackRock Inc. (3.46%), Price T Rowe Associates Inc. MD (2.85%) and State Street Corp (2.78%). Insiders that own company stock include Ai Day1 Llc, Charles N York II, Jeremy Bender, Julie Papanek Grant, Michael Gladstone, Papanek Julie Grant, Pharmaceutical Co Ltd Takeda, Samuel C Blackman, Venture Fund Xi LP Atlas and Xi LP Canaan.
View institutional ownership trends
.

How do I buy shares of Day One Biopharmaceuticals?

Shares of DAWN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Day One Biopharmaceuticals' stock price today?

One share of DAWN stock can currently be purchased for approximately $21.22.

How much money does Day One Biopharmaceuticals make?

Day One Biopharmaceuticals (NASDAQ:DAWN) has a market capitalization of $1.56 billion.

How can I contact Day One Biopharmaceuticals?

Day One Biopharmaceuticals' mailing address is 395 OYSTER POINT BLVD STE 217, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is dayonebio.com. The company can be reached via phone at 650-484-0899 or via email at hans@lifesciadvisors.com.

This page (NASDAQ:DAWN) was last updated on 12/2/2022 by MarketBeat.com Staff